Alnylam Pharmaceuticals, Inc., 10% Owner at Regulus Therapeutics Inc. ("RGLS"), sold 7,600 shares at $7.91 ($60K) on 2014-06-27, disclosed to the SEC on 2014-06-27.
Scheduled sale ($60k) by 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.84 | 2,750 | $22K | 36.0% |
| 2 | $7.89 | 1,700 | $13K | 22.4% |
| 3 | $7.91 | 3,150 | $25K | 41.6% |
| Total | $7.88 avg | 7,600 | $60K | 100% |
| Filing → |
| RGLS | SELL | 2014-10-24 | $1.6M | — | Filing → |
| RGLS | SELL | 2014-10-17 | $81K | — | Filing → |
| RGLS | SELL | 2014-10-10 | $66K | — | Filing → |